Retatrutide: Designed to Last One of the newest GLP-1 medications in development is retatrutide , a triple agonist (GLP-1, GIP, and glucagon receptors) designed with an approximate 6-day half-life , thanks to advanced pharmaceutical engineering
Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction
Liver fat decreases out of proportion to total weight reduction
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities, as per the MHRA Summary of Product Characteristics
Suppose you and your clinician agree to discontinue
Anyone looking for a needle-free option, members transitioning from injectables, or those wanting lighter ongoing metabolic support
